Page 46 - Confidence Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. In this randomized controlled trial, patients with ulcerative colitis taking mirikizumab had higher rates of clinical remission compared to those taking a placebo. 2. Opportunistic infections occurred more frequently in the mirikizumab group. Evidence Rating Level: 1 (Excellent) Study Rundown: Recent clinical trials and approval of monoclonal antibody treatments for ulcerative colitis suggest interleukin-23

Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this podcast, twice a month, we cover the latest in healthcare news and research evidence. Our episode is live! Episode Description We begin this episode by discussing our article of the week from the New England

1. In this randomized controlled trial, the Eat, Sleep, Console approach resulted in a significantly shortened time to medical readiness for discharge in neonates with opioid withdrawal syndrome. 2. There was no significant difference between usual care and the Eat, Sleep, Console approach in the incidence of adverse outcomes. Evidence Rating Level: 1 (Excellent) Study

1. In this randomized controlled trial, cyclophosphamide-tacrolimus-mycophenolate mofetil was associated with lower rates of graft-versus-host disease (GVHD) compared to tacrolimus-methotrexate in patients undergoing hematopoietic stem-cell transplantation (HSCT). 2. There were no significant differences between groups for overall survival. Evidence Rating Level: 1 (Excellent) Study Rundown: GVHD is a major complication of HSCT. The combination of

1. In this randomized controlled trial of patients with atrial fibrillation who had an acute ischemic stroke, early versus late anticoagulation resulted in a comparable incidence of 30-day adverse events. 2. Risk of death from any cause or disability was similar at 90 days between the early and late anticoagulation groups. Evidence Rating Level: 1